BMS partners with British biotech for late-stage cancer combo trials with Opdivo

"BMS partners with British biotech for late-stage cancer combo trials with Opdivo" - Anyone else catch this?

The combination will be similarly with another oncolytic virus (i.e. enadenotucirev) with Opdivo. In light of the showdown between Merck and BMS, I read somewhere that BMS was leading with its Opdivo product in terms of revenue and cancer indications than Merck. This should hopefully add further pressure on Merck especially if BMS have partnered to look at a combination with another developmental oncolytic virus.